[HTML][HTML] Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ (1–42), pTau and tTau CSF immunoassays
K Blennow, LM Shaw, E Stomrud, N Mattsson… - Scientific reports, 2019 - nature.com
We evaluated the performance of CSF biomarkers for predicting risk of clinical decline and
conversion to dementia in non-demented patients with cognitive symptoms. CSF samples …
conversion to dementia in non-demented patients with cognitive symptoms. CSF samples …
Cognitive impairment and dementia after stroke: design and rationale for the DISCOVERY study
Stroke is a leading cause of the adult disability epidemic in the United States, with a major
contribution from poststroke cognitive impairment and dementia (PSCID), the rates of which …
contribution from poststroke cognitive impairment and dementia (PSCID), the rates of which …
Mild cognitive impairment: disparity of incidence and prevalence estimates
A Ward, HM Arrighi, S Michels, JM Cedarbaum - Alzheimer's & Dementia, 2012 - Elsevier
BACKGROUND: The purpose of conducting this study was to identify areas of concordance
and sources of variation for the published rates of prevalence and incidence associated with …
and sources of variation for the published rates of prevalence and incidence associated with …
Monoaminergic neuropathology in Alzheimer's disease
None of the proposed mechanisms of Alzheimer's disease (AD) fully explains the distribution
patterns of the neuropathological changes at the cellular and regional levels, and their …
patterns of the neuropathological changes at the cellular and regional levels, and their …
Alzheimer's disease
CL Masters, R Bateman, K Blennow… - Nature reviews disease …, 2015 - nature.com
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20
years) and an average clinical duration of 8–10 years. The disease has an estimated …
years) and an average clinical duration of 8–10 years. The disease has an estimated …
[HTML][HTML] Critical appraisal of amyloid lowering agents in AD
B Decourt, F Boumelhem, ED Pope III, J Shi… - Current Neurology and …, 2021 - Springer
Abstract Purpose of Review According to the amyloid cascade hypothesis, removing
amyloid beta (Aβ) should cure Alzheimer's disease (AD). In the past three decades, many …
amyloid beta (Aβ) should cure Alzheimer's disease (AD). In the past three decades, many …
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
H Kvartsberg, FH Duits, M Ingelsson, N Andreasen… - Alzheimer's & …, 2015 - Elsevier
Introduction Synaptic dysfunction is an early event in Alzheimer's disease (AD)
pathogenesis and directly related to cognitive impairment. Consequently, synaptic …
pathogenesis and directly related to cognitive impairment. Consequently, synaptic …
[HTML][HTML] Tau in neurodegenerative disease
YL Gao, N Wang, FR Sun, XP Cao… - Annals of translational …, 2018 - ncbi.nlm.nih.gov
Tau, a microtubule-associated protein, is the main component of the intracellular filamentous
inclusions that are involved in neurodegenerative diseases known as tauopathies, including …
inclusions that are involved in neurodegenerative diseases known as tauopathies, including …
[HTML][HTML] Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics
Alzheimer's Disease (AD) currently affects more than 5 million Americans, with numbers
expected to grow dramatically as the population ages. The pathophysiological changes in …
expected to grow dramatically as the population ages. The pathophysiological changes in …
Emerging understanding of the protein corona at the nano-bio interfaces
Upon entering the physiological environment, nanoparticles (NPs) are immediately
surrounded by a complex and tightly bound layer of biomolecules, or '(hard) protein corona' …
surrounded by a complex and tightly bound layer of biomolecules, or '(hard) protein corona' …